The gene coding for ubiquilin 1 (UBQLN1) is located near a linkage peak on chromosome 9q22.2 and it also impacts the function of presenilin proteins involved in early-onset Alzheimer's disease (AD). Recently, genetic variation in UBQLN1 has been shown to affect the risk of AD in two independent family-based samples. The purpose of this study was to confirm the reported association in a large case-control sample and to also examine the association of UBQLN1 SNPs with quantitative measures of AD progression, namely age-atonset (AAO), disease duration and Mini-Mental State Examination (MMSE) score. We examined the associations of three SNPs in the UBQLN1 gene (intron 6/A > C, intron 8/T > C and intron 9/ A > G) in up to 978 LOAD cases and 808 controls. All SNPs were in significant linkage disequilibrium (P < 0.0001). While modest significant associations were observed in the singlesite regression analysis, 3-site haplotype analysis revealed significant associations (P < 0.0001 for overall haplotype analysis). One common haplotype (H4) defined by intron 6/A-intron 8/Cintron 9/G alleles was associated with AD risk and one less common haplotype (H5) defined by intron 6/C-intron 8/C-intron 9/A alleles was associated with protection. The adjusted odds ratios with potentially one and two copies of risk haplotype H4 were 1.5 (95% CI: 0.99-2.26; P = 0.054) and 3.66 (95% CI: 1.43-9.39; P = 0.007), respectively, and odds ratio for haplotype H5 carriers was 0.31 (95% CI: 0.10-0.95; P = 0.0398). In addition to disease risk, the homozygosity of the risk haplotype was also associated with older AAO, longer disease duration and lower MMSE score. In summary, our data from a large case-control cohort indicate that genetic variation in the UBQLN1 gene has a modest effect on risk, AAO and disease duration of AD. Our haplotype data suggest the presence of additional putative functional variants either in the UBQLN1 gene or nearby genes and provide strong justification for additional work in this region on chromosome 9.
Introduction
The genetics of late-onset Alzheimer's disease (LOAD) is complex with the possible involvement of several genes and interaction among them and/or environmental factors. To date the APOE*4 allele of the apolipoprotein E (APOE) gene on chromosome 19q13 is the only established susceptibility genetic marker for LOAD and it explains 20-29% of the risk 1, 2 and < 10% of the variation in age-at-onset (AAO) of AD. 2 This indicates that additional genes need to be identified that affect risk and/or AAO of AD. Linkage studies have identified several promising chromosomal regions to harbor additional LOAD genes, with the strongest evidence on chromosome 12, 10, 9 and 6. 3 Two linkage peaks on chromosome 9, one each on 9p and 9q, have been identified in overlapping family samples, mainly derived from the National Institute of Mental Health (NIMH) Genetic Initiative Alzheimer's Disease study, [4] [5] [6] but not in Caribbean Hispanic families. 7 The strongest evidence of linkage in the full NIMH data set was observed among LOAD families at 87.9 Mb on 9q22 with a lod score of 2.9. 6 In order to identify the LOAD gene on 9q22, recently Bertram et al. 8 genotyped 19 SNPs in three positional and biological candidate genes in this region, including seven SNPs in amyloid beta precursor protein binding A1 (APBA1) at 69.3 Mb, five SNPs in Ubiquilin 1 (UBQLN1) at 83.5 Mb and seven SNPs in ATP-binding cassette A1 (ABCA1) at 104.6 Mb in the NIMH families. Two of the five SNPs in UBQLN1, intron 8 (rs12344615) and intron 9 (rs2781002), showed significant associations, which was confirmed in a second family-based sample from the Consortium on Alzheimer's Genetics (CAG) and also identified an additional significant SNP in intron 6 (rs2780995). The combined data from the two family samples showed the strongest association with the intron 8 SNP followed by intron 9 and 6 SNPs.
The purpose of the present study was to replicate the reported family-based association with three UBQLN1 SNPs in a large case-control sample. In addition to disease risk, we also evaluated the role of the UBQLN1 SNPs with the quantitative measure of AD progress, including AAO, disease duration and Mini Mental State Examination (MMSE) score.
Materials and methods

Subjects
A total of 978 white LOAD sporadic subjects and 808 older white control subjects were included in the initial genotype screen. The LOAD (X60) cases (66% female, 28.1% autopsy-confirmed) were from the University of Pittsburgh Alzheimer's Disease Research Center (ADRC). The mean age of patients was 77.77 (s.d.) 6.3 years with a mean AAO of 72.776.4 years. Clinical diagnoses of the patients were made according to the NINCDS/ADRDA criteria. 9 The ADRC follows a standard evaluation protocol, which includes medical history, general medical and neurological examinations, a psychiatric interview, neuropsychological testing and a MRI scan. The controls (61.9% female, mean age 75.275.6 years) were recruited from the same Western Pennsylvania region as the cases, and were determined to be cognitively intact following extensive clinical examination as described elsewhere. 10 The severity of cognative impairment was assessed from the MMSE scores measured at baseline and during the last phase of the study. 11 This study was approved by the University of Pittsburgh Institutional Review Board.
Genotyping
Genotyping of the three UBQLN1 SNPs was obtained using the fluorescence polarization method as described elsewhere. 8 
Statistical analyses
Allele frequencies were calculated by the allele counting method. Goodness of fit to Hardy-Weinberg expected proportions was examined by w 2 test. The differences in genotype frequencies between cases and controls were tested by w 2 tests. The pair-wise linkage disequilibrium (LD) between markers was estimated using the D 0 method. 12 Multiple logistic regression models were used to examine the association of each genetic marker with AD. The models included covariates, such as age (AAO for cases, age at APOE genotyping for controls), gender, and APOE status (APOE*4 and non-APOE*4 carriers) to obtain ORs that were adjusted for the effects of these significant variables. The interaction between APOE and UBQLN1 SNP in effecting the risk of AD was included in the regression models. The mean AAO between different genotype groups were compared using one-way analysis of variance (ANOVA) and adjusted for the effects of gender and APOE*4. The disease duration was estimated by subtracting the AAO from the age-at-death. All computations were performed using R statistical 1.8.1 program. 13 The three-site haplotype frequencies were estimated using the Expectation-Maximization algorithm in the EH software program (http://linkage.rockefeller.edu/ott/ eh.htm). Kaplan-Maier survival analysis was also used to compare the AAO between genotypes.
Results
Association of UBQLN1 SNPs with AD risk
Of the total 1786 subjects (978 cases, 808 controls) genotyped for three UBQLN1 SNPs, genotype success rate was 79, 97 and 97% for the intron 6, 8 and 9 SNPs, respectively. In all, 10% of the subjects for each SNP were regenotyped to confirm the validity of genotypes. Table 1 presents the genotype and allele frequencies data in LOAD cases and controls for the three UBQLN1 SNPs examined. No statistically significant deviations from Hardy-Weinberg equilibrium were found in either cases or controls. The frequency of the less common allele for intron 6 SNP was lower in cases than controls (35 vs 38.9%; P = 0.031). On the other hand, the frequencies of the less common alleles were higher in cases than controls for intron 8 (20 vs 17.6%; P = 0.068) and intron 9 (40.2 vs 37.3%; P = 0.079) SNPs.
Logistic regression analysis including age, sex, APOE, UBQLN1 SNP and interaction between APOE and UBQLN1 was performed to assess the role of UBQLN1 SNPs with AD risk. Logistic regression analysis included one UBQLN1 SNP at a time to avoid colinearity ( Table 2 ). The strongest associations were with the CC genotype of the intron 6 SNP (odds ratio (OR) = 0.55, 95% CI: 0.34-0.91; P = 0.019) and C allele carriers of intron 8 SNP (OR = 1.34, 95% CI: 1-1.78; P = 0.049). No statistically significant interactions were found between UBQLN1 SNPs and APOE.
Haplotype analysis and AD risk Pair-wise linkage disequilibrium analysis between three UBQLN1 SNPs revealed significant association (P < 0.0001): |D 0 | values were 0.842 between intron 6 and 8, 0.980 between intron 6 and 9, and 0.859 between intron 8 and 9. Despite the significant associations, the three SNPs were not completely correlated and thus are useful for haplotype analysis. We performed EH-based haplotype analysis to calculate 3-site haplotye frequencies between cases and controls (Table 3) . A total of seven haplotypes were observed and their overall distribution was significantly different between cases and controls (P < 0.0001). Individually, the frequency of haplotype H4 carrying risk alleles at all three sites (intron 6/A-intron 8/C-intron 9/G) was higher in cases than controls (19.4 vs 14.1%) and the frequency of haplotype H1 carrying all three protective alleles (intron 6/C-intron 8/T-intron 9/A) was lower in cases than controls (34.1 vs 37.2%). A less common haplotype H5, carrying two protective alleles and one risk allele (intron 6/C-intron 8/C-intron 9/A), was associated with protection against AD risk (0.3 vs 1.7%). We performed logistic regression analysis on joint 3-site genotypes and calculated multilocus ORs after adjusting for the effects of age, sex and APOE. The homozygosity of the most common haplotype (joint genotype: CC-TT-AA) was used as the base joint-genotype for comparison. One copy of the risk haplotype H4 (A-C-G) was potentially present in 29.4% of the subjects (joint genotypes: AC-TC-AG, AA-TC-AG, AA-TC-GG, AA-CC-AG and AC-TC-GG) and it had OR of 1.50 (95% CI: 0.99-2.26; P = 0.054). On the other hand, 2.6% of subjects carrying two copies of risk haplotype H4 (joint genotype AA-CC-GG) had OR of 3.66 (95% CI: 1.43-9.39; P = 0.007). The low frequency protective haplotype H5 (C-C-A) was potentially present in 1.74% of the subjects (joint genotypes: AC-TC-AA, CC-TC-AA, AC-CC-AA and CC-CC-AA) and it was associated with an OR of 0.31 (95% CI: 0.10-0.95; P = 0.0398).
Since the number of individuals typed for intron 6 was less than the other two SNPs and the 3-site haplotype analysis included individuals based on intron 6 results (n = 1378), we also performed post hoc two-site haplotype analyses. No single allele at any one site defined a given risk or protective haplotype; it was rather a unique combination of alleles at all three sites that was associated with either risk or protection. For example, for intron 6-8 combination (n = 1385; P = 0.002), the intron 6/A-intron 8/C haplotype conferred risk (20.1 vs 14.9%) and intron 6/C-intron 8/C haplotype conferred protection (0.3 vs 2%). Likewise, for intron 8 -intron 9 combination (n = 1688; P = 0.0019), the intron 8/C-intron 9/G haplotype was associated with risk (19.3 vs 15.3%) and intron 8/C-intron 9/A haplotype was associated with protection (1 vs 2.4%). These two-site haplotype analyses suggest that the intron 6/A and intron 9/G alleles determine risk and intron 6/C and intron 9/A alleles determine protection and this appears to provide confirmation in the intron 6-intron 9 haplotype analysis (n = 1397; P = 0.0024) where the haplotype containing intron 6/A-intron 9/G alleles was associated with risk (40.4 vs 36.3%) and haplotype containing intron 6/C-intron 9/A was associated with protection (34.4 vs 38.8%). However, the combination of intron 6/A-intron 9/G haplotype is not sufficient to determine risk as this requires the presence of intron 8/C allele as shown in haplotype H4 (A-C-G) in 3-site haplotype and genotype analysis. On the other hand, intron 8/C allele is also present in combination with intron 6/C and intron 9/A allele as part of the less common protective haplotype H5 (C-C-A). These data strongly suggest that yet to be identified functional risk and protective alleles are likely present on haplotypes H4 and H5, respectively.
UBQLN1 SNPs and AD-related quantitative traits
We also examined the association of UBQLN1 SNPs with three quantitative traits related to AD, namely AAO, disease duration and MMSE scores (Table 4) . Intron 8 and 9 SNPs showed association with AAO where the intron 8/CC genotype (75.376.5 year vs 72.676.1 year; P = 0.022) and intron 9/GG genotype (74.076 year vs 72.576.5 year; P = 0.009) were associated about 2 year older AAO than the other two genotypes and it was confirmed by the KaplanMaier survival analysis (Figure 1 ). The intron 8 and 9 SNPs explained 0.47 and 0.78% of the variation, respectively in AAO. A trend of association was observed between MMSE score and all three SNPs in a recessive fashion, particularly the intron 8/CC genotype had the lowest MMSE score (P = 0.024). The intron 8/CC genotype also had the longest disease duration (P = 0.004). Table 4 also presents comparison of AD-related quantitative traits among joint 3-site genotypes based on the presence of potentially no copy, one copy and two copies of risk haplotype H4 (intron 6/A-8/C-9/G). Joint 3-site genotype analysis revealed that the homozygosity of the risk haplotype H4 (AA-CC-GG) was associated with oldest AAO (75.376.7 vs 72.376.7 year), longest disease duration (13.772.4 vs 10.073.9 year) and lowest MMSE score (19.475.9 vs 21.674.5).
Discussion
The gene coding for UBQLN1 is located near a linkage peak for LOAD on chromosome 9q22.2 6 and it appears to play an important role in regulating the metabolism of presenilin proteins, 14 mutations in which cause early-onset AD. Thus UBQLN1 is both a positional and biological candidate gene for AD. Recently, Figure 1 Kaplan-Maier survival analysis for age-at-onset (AAO). The AAO is plotted against the proportion unaffected by AD at a given age. While there is no effect of the intron 6 genotype on AAO, the intron 8/CC and intron 9/GG genotypes are associated with older AAO than the other two genotypes within each SNP.
Bertram et al. 8 have examined five UBQLN1 SNPs encompassing in a single haplotype block and found significant associations with three SNPs in intron 6, 8 and 9. The strongest association was observed with the intron 8 SNP followed by intron 9 and 6 SNPs using family-based association and pedigree disequilibrium tests in the combined family sample. Furthermore, one haplotype defined by the intron 8/C allele was associated with AD risk. The purpose of this study was to replicate reported family-based associations with three SNPs in a large case-control cohort. Since the reported effect size was small, we sought to replicate the finding in a well-powered study and successfully genotyped up to 949 LOAD cases and 797 controls.
The allele frequencies of all SNPs were modestly different between cases and controls and the strongest associations were seen with the intron 6 and 8 SNPs in the logistic regression analysis. While the homozygosity of the intron 6/C allele was associated with protection (OR = 0.55; P = 0.019), the heterozygosity of intron 8/CT genotype was associated with risk (OR = 1.34; P = 0.049). Unlike Bertram et al.'s finding, we did not observe a dose-dependent effect of the intron 8/C allele in our sample; however, our OR of 1.34 in CT heterozygotes was similar to the reported OR of 1.5 among heterozygotes in the combined family data.
In contrast to the single-site analysis, the 3-site haplotype analysis yielded stronger associations both in the overall and individual haplotype comparisons between cases and controls. The marginally riskassociated alleles in single-site analysis (intron 6/A, 8/C and 9/G) demonstrated significant association together as part of haplotype H4. The carriers of potentially one copy of haplotype H4 were associated with 1.5-fold risk, which was doubled in carriers of two copies of haplotype H4 (OR: 3.66). Previously, Bertram et al. 8 reported that a 5-site haplotype was almost exclusively defined by the intron 8/C allele. However, our data indicate that intron 8/C allele is not exclusively associated with increased AD risk because a less common haplotype H5 (intron 6/C-intron 8/C-intron 9/A) containing intron 8/C allele was protective and had an OR of 0.31. Two-site haplotype analysis also confirmed that no single allele at any one 10 transcription factor CP2 (OR = 1.51) 15 and oxidized LDL receptor 1 (OR = 1.52) 16 genes. In addition to disease risk, we also examined the association of UBQLN1 SNPs with quantitative measures of AD progression, including AAO, disease duration and MMSE scores. The strongest association was observed between the intron 9 and intron 8 SNPs and AAO where the homozygosity of the less common allele at each site (intron 8/CC, intron 9/ GG) was associated with an older AAO than the other two combined genotypes within each SNP. About 0.5 and 0.8% of the variation in AAO was attributable to the intron 8 and intron 9 SNPs, respectively. Although this contribution is small, it is consistent with a simulation study in which two of the seven postulated genes for AAO of AD have < 1% effect each on AAO. 17 The intron 8/CC genotype was also associated with longer disease duration (14.873.2 vs 9.973.5 year; P = 0.0041) and lower MMSE score (20.374.6 vs 21.874.5; P = 0.024) than the other two combined intron 8 genotypes. While the singlesite data suggest that the intron 8 allele that affects alternative splicing 8 may be functionally relevant to AD-related quantitative traits, our joint 3-site genotype data suggest that homozygosity of the risk haplopotype H4 (AA-CC-GG) is associated with oldest AAO, longest disease duration and lowest MMSE score (see Table 4 ). Since the homozygosity of risk haplotype H4 also confers AD risk, our data strongly suggest that this haplotype is associated with a milder form of AD and that other sequence variation in the UBQLN1 gene may be more relevant to AD etiology than the three SNPs examined in this study. While our study was in progress, Slifer et al. 18 reported no association of intron 8 or other UBQLN1 variants they examined with AD risk in either a family-based sample or a case-control sample, however, they found a significant association between the intron 8/CC homozygosity and older AAO in their case-control sample. Slifer et al. 18 also found an additional significant association with AAO in their family-based data with a different UBQLN1 SNP. In their reply to Slifer et al., 18 Bertram and Tanzi 19 reported another variant in the promoter of UBQLN1 to be associated with AD risk. Although the results of Bertram et al. 8, 12 and Slifer et al. 18 differ from each other, our data from a large case-control sample corroborate the findings of both groups because our sample shows association with both risk and AAO of AD. Furthermore, we provide new information that UBQLN1 genetic variation may also affect disease duration and MMSE score.
The collective published 8, 18, 19 and our data suggest that genetic variation in the UBQLN1 gene may modulate the risk and/or AAO of AD. The lack of consistency between the examined UBQLN1 SNPs and the risk or AAO of AD between theses studies warrant a comprehensive screening of the entire genetic variation in the UBQLN1 gene in order to identify puntative functional variants. Alternatively, genes adjacent to UBQLN1 harbor functional variants and the observed associations with UBQLN1 variants represent nonrandom association with these functional variants.
